Kelley Eli F, Olson Thomas P, Curry Timothy B, Sprissler Ryan, Snyder Eric M
School of Kinesiology, University of Minnesota, Minneapolis, MN, USA.
Geneticure, Inc, Rochester, MN, USA.
Clin Med Insights Cardiol. 2019 May 3;13:1179546819845883. doi: 10.1177/1179546819845883. eCollection 2019.
The purpose of this study was to determine the effectiveness of a simple algorithm to mathematically predict a patients' response to blood pressure (BP) therapy using functional genes in the 3 major organ systems involved in hypertension.
Eighty-six patients with controlled hypertension completed 1 study visit consisting of a buccal swab collection, measurement of office BP, and a medical chart review for BP history. Genes in the analysis included 14 functional alleles in 11 genes. These genotypes were mathematically summed per organ system to determine whether a patient would likely respond to target therapy.
Patients recommended to and taking a diuretic had significantly higher rates of control (<120/<80) than patients recommended but not taking this drug class (0.2 ± 0.1 and 0.03 ± 0.03, respectively). Furthermore, there was a difference between patients genetically recommended and taking an angiotensin receptor blocker (ARB) vs patients recommended but not taking an ARB for the lowest diastolic blood pressure (DBP) and mean arterial pressure (MAP) recorded in the past 2 years (DBP = 66.2 ± 2.9 and 75.3 ± 1.7, MAP = 82.3 ± 2.8 and 89.3 ± 1.5, respectively). In addition, there was a nonsignificant trend for greater reductions in ΔSBP, ΔDBP, and ΔMAP in patients on recommended drug class for beta-blockers, diuretics, and angiotensin II receptor blockers vs patients not on these classes.
The present study suggests that simple mathematical weighting of functional genotypes known to control BP may be ineffective in predicting control. This study demonstrates the need for a more complex, weighted, multigene algorithm to more accurately predict BP therapy response.
本研究旨在确定一种简单算法的有效性,该算法通过涉及高血压的3个主要器官系统中的功能基因,以数学方式预测患者对血压(BP)治疗的反应。
86例高血压得到控制的患者完成了1次研究访视,包括采集颊拭子、测量诊室血压以及回顾病历中的血压病史。分析的基因包括11个基因中的14个功能等位基因。这些基因型按器官系统进行数学求和,以确定患者是否可能对目标治疗有反应。
被推荐使用利尿剂并正在服用的患者,其血压控制率(<120/<80)显著高于被推荐但未服用该类药物的患者(分别为0.2±0.1和0.03±0.03)。此外,在过去2年记录的最低舒张压(DBP)和平均动脉压(MAP)方面,基因推荐并服用血管紧张素受体阻滞剂(ARB)的患者与被推荐但未服用ARB的患者之间存在差异(DBP分别为66.2±2.9和75.3±1.7,MAP分别为82.3±2.8和89.3±1.5)。此外,与未服用β受体阻滞剂、利尿剂和血管紧张素II受体阻滞剂的患者相比,服用这些推荐药物类别的患者在ΔSBP、ΔDBP和ΔMAP方面有更大降低的趋势,但差异不显著。
本研究表明,已知可控制血压的功能基因型的简单数学加权在预测血压控制方面可能无效。本研究表明需要一种更复杂、加权的多基因算法来更准确地预测血压治疗反应。